Celldex Therapeutics (CLDX) Depreciation & Amortization (CF) (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Depreciation & Amortization (CF) of $854000.0 for Q1 2026, down 1.5% year-over-year from $867000.0 in Q1 2025, and up 4.66% quarter-over-quarter from $816000.0 in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $854000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 1.5% year-over-year to $854000.0; the TTM figure through Mar 2026 stood at $3.4 million (up 3.0% YoY), while the FY2025 annual figure was $3.4 million, up 6.39% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $854000.0, up from $816000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $873000.0 in Q2 2025, with the low at $671000.0 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $786000.0 (2024), against an average of $783235.3.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) dropped 13.38% in 2022, then climbed 14.31% in 2023.
- Celldex Therapeutics' Depreciation & Amortization (CF) stood at $673000.0 in 2022, then increased by 12.78% to $759000.0 in 2023, then rose by 7.91% to $819000.0 in 2024, then fell by 0.37% to $816000.0 in 2025, then grew by 4.66% to $854000.0 in 2026.
- Business Quant data shows CLDX's Depreciation & Amortization (CF) at $854000.0 in Q1 2026, $816000.0 in Q4 2025, and $824000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn | 902,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 902,000.00 |
| Mar 31, 2026 | 854,000.00 |
| Dec 31, 2025 | 816,000.00 |
| Sep 30, 2025 | 824,000.00 |
| Jun 30, 2025 | 873,000.00 |
| Mar 31, 2025 | 867,000.00 |
| Dec 31, 2024 | 819,000.00 |
| Sep 30, 2024 | 786,000.00 |
| Jun 30, 2024 | 797,000.00 |
| Mar 31, 2024 | 775,000.00 |
| Dec 31, 2023 | 759,000.00 |
| Sep 30, 2023 | 767,000.00 |
| Jun 30, 2023 | 756,000.00 |
| Mar 31, 2023 | 726,000.00 |
| Dec 31, 2022 | 673,000.00 |
| Sep 30, 2022 | 671,000.00 |
| Jun 30, 2022 | 741,000.00 |
| Mar 31, 2022 | 811,000.00 |
| Dec 31, 2021 | 777,000.00 |
| Sep 30, 2021 | 752,000.00 |